Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

• Eli Lilly and Co recently reported strong financial performance, beating consensus estimates with earnings per share of $8.38 compared to the expected $6.40, while revenue grew 47.7% year-over-year to $22.97 billion, demonstrating robust demand for its products.
• The company's oral GLP-1 treatment, Foundayo, is expected to continue gaining market share over the next 12 months according to Bank of America, and European regulators have recommended its approval, which could significantly expand the company's reach in the obesity drug market.
• Eli Lilly and Co has secured a strategic collaboration with Metis TechBio for up to $1.1 billion for AI-enabled drug-delivery technology, which broadens its future product base beyond obesity medicines and supports long-term innovation.
• The stock is currently trading at $1,242.76, which is below the consensus price target of $1,313.43, suggesting potential upside for investors as analysts maintain a "Moderate Buy" rating with 24 Buy ratings and only 1 Sell rating.
• Positive clinical data for Omvoh in pediatric ulcerative colitis, where 50% of induction responders achieved clinical remission at one year, supports potential label expansion and strengthens the company's immunology portfolio.